FDA Adds 18 Tobacco Harmful Constituents and Seeks Comment on 3 More

Apr.24
FDA Adds 18 Tobacco Harmful Constituents and Seeks Comment on 3 More
U.S. Food and Drug Administration published a Federal Register notice finalizing the addition of 18 constituents to the established list of Harmful and Potentially Harmful Constituents in tobacco products. With the update, the list now contains 111 constituents. FDA also proposed adding three more constituents to the list and opened a public comment period ending at 11:59 p.m. ET on May 26, 2026.

Key Takeaways

  • FDA published a Federal Register notice on April 22, 2026, finalizing the addition of 18 constituents to the established HPHC list.
  • The updated HPHC list now contains 111 constituents.
  • FDA said the listed chemicals may be found in tobacco products including e-cigarettes, hookah tobacco and cigars, as well as in their smoke and/or aerosol.
  • FDA also proposed adding three more constituents: pulegone, furfuryl alcohol and methyl eugenol.
  • Public comments on the three proposed additions must be submitted by 11:59 p.m. ET on May 26, 2026.

2Firsts, April 24, 2026 

 

The U.S. Food and Drug Administration published a Federal Register notice finalizing the addition of 18 constituents to the established list of Harmful and Potentially Harmful Constituents in tobacco products. With this update, the list now contains 111 constituents.

 

FDA added 18 constituents to the HPHC list


FDA said the HPHC list identifies chemicals and chemical compounds found in tobacco products or in tobacco smoke and/or aerosol that cause or could cause harm to users or non-users of tobacco products.

 

The agency said the updated list improves transparency for the public and provides greater clarity for industry. For the public, the list highlights certain toxic chemicals in tobacco products for which there is extensive evidence of harm, or potential harm, to human health. For industry, the updated list identifies areas of focus for FDA’s review of new tobacco product applications.

 

FDA also said the HPHC list is not a ban. Under the Food, Drug and Cosmetic Act, industry is required to report a full statement of a product’s constituents, including HPHCs, to FDA.

 

The total number of listed constituents rose to 111


FDA said that with the 18 additional constituents, the established list now contains 111 HPHCs. The agency said the chemicals on the updated list may be found in tobacco products, including e-cigarettes, hookah tobacco and cigars, as well as in their smoke and/or aerosol.

 

FDA published the names of the 18 newly added constituents


FDA said it had published a request for public comments in August 2019 on HPHCs proposed for inclusion on the established list. After considering public comments and other scientific information, the agency finalized the following 18 additions:

 

Acetic Acid
Acetoin, also known as 3-hydroxy-2-butanone
Acetyl Propionyl, also known as 2,3-pentanedione
Benzyl Acetate
Butyraldehyde
Diacetyl
Diethylene Glycol
Ethyl Acetate
Ethylene Glycol
Furfural
Glycerol
Glycidol
Isoamyl Acetate
Isobutyl Acetate
Methyl Acetate
n-Butanol
Propionic Acid
Propylene Glycol

 

FDA proposed three additional constituents for inclusion


FDA also said that, based on public comments suggesting constituents beyond those in the 2019 notice, it is proposing to add three additional constituents to the established list and is requesting public comment. Those three proposed additions are pulegone, furfuryl alcohol and methyl eugenol.

 

The agency said these constituents are often added to e-liquid formulations as flavoring ingredients, but may also be present in other tobacco products such as cigarettes and smokeless tobacco. FDA said comments must be submitted by 11:59 p.m. ET on May 26, 2026, to ensure they are considered.

 

Respiratory toxicants were confirmed as an added criterion


In addition, FDA finalized its tentative conclusion from the 2019 notice that constituents identified by the National Institute for Occupational Safety and Health as respiratory toxicants will be an additional criterion for determining whether a constituent should be included on the HPHC list.

 

FDA said it will continue to revise the list


FDA said it intends to continue revising the established HPHC list as additional criteria are defined and more scientific information becomes available. The agency said this action is part of its ongoing commitment to protecting public health through comprehensive oversight of tobacco products.

Image Source: FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10